Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Organisation › Details

Ionis Pharmaceuticals Inc. (Nasdaq: IONS)

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan and Canada for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen (IONIS-TTRRx), an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Both inotersen and volanesorsen are progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology. *


Period Start 2015-12-01 renamed
  Group Ionis Pharmaceuticals (Group)
  Predecessor Isis Pharmaceuticals Inc. (Nasdaq: ISIS)
Products Industry pharmaceutical
  Industry 2 antisense drug
Person Person Crooke, Stanley T. (Isis Pharmaceuticals 200604 CEO)
Region Region Carlsbad, CA
  Country United States (USA)
  Street 2855 Gazelle Court
  City 92010 Carlsbad, CA
  Tel +1-760-931-9200
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Ionis Pharmaceuticals, Inc.. (8/11/17). "Press Release: Ionis to Independently Advance Inotersen and Ionis-FB-L Rx". Carlsbad, CA.
Record changed: 2019-07-13


Picture [iito] Plain Stupid Simple 650x80px

More documents for Ionis Pharmaceuticals (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top